Endocannabinoid System Found to Play a Role in Chemotherapy-Caused Hearing Loss
Cisplatin chemotherapy disrupts the endocannabinoid system in hearing cells, and blocking the CB2 receptor may actually protect against this damage.
Quick Facts
What This Study Found
Cisplatin treatment downregulated CB2 receptors and disrupted the 2-AG metabolic pathway in auditory hair cells. Counterintuitively, pharmacological blockade of CB2 receptors with SR144528 protected hair cells from cisplatin damage by inhibiting caspase-3 cleavage (a cell death marker).
Key Numbers
Both major endocannabinoids (AEA and 2-AG) were present in auditory hair cells. Cisplatin downregulated CB2R, DAGLb, and ABHD6. CB2 receptor blockade via SR144528 reduced caspase-3 cleavage, a marker of cell death.
How They Did This
Researchers profiled the endocannabinoid system in mouse auditory hair cell lines, established an in vitro cisplatin toxicity model, validated findings in an in vivo mouse model, and tested whether CB2 receptor blockade could protect against damage.
Why This Research Matters
Cisplatin-induced hearing loss affects many cancer patients and has no treatment. Identifying the endocannabinoid system as involved opens an entirely new avenue for protective therapies during chemotherapy.
The Bigger Picture
The counterintuitive finding that blocking (not activating) CB2 receptors protects hearing cells challenges simple assumptions about cannabinoid pharmacology. It suggests the endocannabinoid system role in hearing is more nuanced than in other tissues.
What This Study Doesn't Tell Us
Primarily an in vitro study with some in vivo validation. The cell line (UB/OC1) is derived from mouse tissue and may not perfectly replicate human auditory cells. Translating CB2 blockade to clinical hearing protection requires extensive further research.
Questions This Raises
- ?Could cannabis use during chemotherapy affect hearing loss risk?
- ?Would CB2 receptor antagonists need to be administered locally to the ear, or could systemic treatment work?
Trust & Context
- Key Stat:
- CB2 receptor blockade protected hearing cells from cisplatin damage
- Evidence Grade:
- Early-stage mechanistic study combining in vitro and in vivo mouse models. Novel finding but far from clinical application.
- Study Age:
- 2026 study.
- Original Title:
- Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.
- Published In:
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(4), e71568 (2026)
- Authors:
- Palaniappan, Sakthimala(2), Tisi, Annamaria(3), Di Meo, Camilla(4), Urbano, Cristina, Fenton, Georgina E, Della Valle, Francesco, Fanti, Federico, Compagnone, Dario, Nazarè, Marc, Versnel, Huib, Aramini, Andrea, Allegretti, Marcello, Maccarrone, Mauro
- Database ID:
- RTHC-08536
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids prevent chemotherapy hearing loss?
This study found that blocking (not activating) the CB2 cannabinoid receptor protected hearing cells from cisplatin damage in mice. This is a very early finding that needs much more research before any clinical application.
Why is this counterintuitive?
Most cannabinoid research focuses on activating receptors for therapeutic benefit. Here, blocking a cannabinoid receptor was protective, suggesting the endocannabinoid system plays an unusual role in hearing cell biology.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-08536APA
Palaniappan, Sakthimala; Tisi, Annamaria; Di Meo, Camilla; Urbano, Cristina; Fenton, Georgina E; Della Valle, Francesco; Fanti, Federico; Compagnone, Dario; Nazarè, Marc; Versnel, Huib; Aramini, Andrea; Allegretti, Marcello; Maccarrone, Mauro. (2026). Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(4), e71568. https://doi.org/10.1096/fj.202502888RR
MLA
Palaniappan, Sakthimala, et al. "Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.." FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. https://doi.org/10.1096/fj.202502888RR
RethinkTHC
RethinkTHC Research Database. "Unraveling Endocannabinoid Signaling Pathways in Cisplatin-I..." RTHC-08536. Retrieved from https://rethinkthc.com/research/palaniappan-2026-unraveling-endocannabinoid-signaling-pathways
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.